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Abstract  
 
Selenium-enriched yeast (Se-yeast) is a common form of selenium used to supplement dietary 
intake of this important trace mineral.  However, its availability within the EU is under threat owing 
to concerns expressed by the EC Scientific Committee on Food that Se-yeast supplements are 
poorly characterised and could potentially cause the build up of selenium in tissues to toxic levels. 
This review examines the validity of these concerns.  Diagrams of the biosynthesis and metabolism 
of selenium compounds show which species can be expected to occur in Se-yeast preparations.   Se-
yeast manufacture is described together with quality control measures applied by reputable 
manufacturers.  The way in which speciation of Se-yeast is achieved is explained and results on 
amounts of selenium species in various commercial products are tabulated.  In all cases described, 
selenomethionine is the largest single species, accounting for 54-74% of total selenium.  Se-yeast is 
capable of increasing the activity of the selenoenzymes and its bioavailability has been found to be 
higher than that of inorganic selenium sources in all but one study.  Intervention studies with Se-
yeast have shown the benefit of this form in cancer prevention, immune response and HIV 
infection.  Of around one dozen supplementation studies, none has shown evidence of toxicity even 
up to an intake level of 800 µg/d selenium over a period of years.  It is concluded that Se-yeast from 
reputable manufacturers is adequately characterised, of reproducible quality, and that there is no 
evidence of toxicity even at levels far above the EC Tolerable Upper Intake Level of 300 µg/d. 
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Introduction 
The trace mineral selenium is a crucial nutrient for human health.  It is a component of a number of 
important selenoproteins and enzymes required for such functions as antioxidant defence, reduction 
of inflammation, thyroid hormone production, DNA synthesis, fertility and reproduction (Rayman, 
2000).  It can also be converted in the body to selenium metabolites that are thought to reduce the 
blood supply to tumours and kill cancer cells (Combs & Lü, 2001).  Adequate dietary intakes of 
selenium are therefore essential. 
 
Selenium enters the food chain through plants and its concentration in foods is determined by a 
number of geological and geographical factors:- (i) soil selenium species and concentration, (ii) pH, 
which determines to some extent the nature of the selenium species; (iii) amounts of organic matter, 
iron hydroxides, aluminium compounds and clay that can bind selenium reducing its bioavailability 
to plants, (iv) amounts of sulphur species (e.g. from sulphur fertilisers) that can compete with 
selenium for absorption; (v) rainfall that can leech selenium out of the soil and (vi) soil microbes 
that can convert insoluble forms of selenium to soluble forms (Diplock, 1993; Fordyce et al. 2000; 
Johnson et al. 2000; Adams et al. 2002).  In some parts of the world where selenium is 
insufficiently available to plants, selenium-deficiency diseases have been identified such as Keshan 
disease, an endemic cardiomyopathy found in the North East of China (Keshan Disease Research 
Group, 1979) that formerly caused many deaths.  Supplementation with selenium has greatly 
reduced the incidence of the condition (Reilly, 1996). 
 
There are other regions of the world, such as the south island of New Zealand and parts of China 
and Europe, where selenium intake may not be adequate for full activity of protective 
selenoenzymes.  Governments have set dietary reference values for selenium intake based on their 
assessment of the amount of selenium required to achieve optimal (or ⅔ optimal) activity of the 
antioxidant selenoenzyme glutathione peroxidase in plasma (Committee on Medical Aspects of 
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Food Policy, 1991; WHO/FAO/IAEA expert group, 1996; Food and Nutrition Board, 2000).  Table 
1 shows daily intake levels of selenium recommended by a number of national or international 
committees while Table 2 is a compilation of up-to-date selenium-intake data for a number of 
countries.  While the intake of selenium in New Zealand appears to have increased in the last 
decade as a result of importation of Australian wheat (Thomson & Robinson 1996; Vannoort et al. 
2000), that in a number of European countries has declined owing to reduced importation of wheat 
from N. America for bread-making that was relatively high in selenium (Rayman 1997; Adams et 
al. 2002).  Comparison of the values in Table 2 with those of Table 1 shows that recommended 
daily intakes are not now achieved in the majority of European countries together with parts of 
China. These recommended intake levels (Table 1), however, do not take into account the fact that 
higher levels of selenium intake appear to confer additional health benefits on the immune system, 
on cancer risk and on HIV symptoms and progression (Rayman 2002, Burbano et al. 2002).  Cancer 
protective intakes of selenium have been calculated separately by two groups (Combs et al. 2001; 
Thomson & Paterson, 2001) to be in the region of 75-125 or 96-120 µg/d, considerably higher than 
currently-recommended intakes. 
 
Combs (2001) has compiled a table of reported concentrations of selenium in serum, plasma or 
whole-blood from 69 countries.  Using the minimum value of 70 µg selenium/L in serum or plasma 
as a criterion of nutritional selenium adequacy as described above (Nève, 1995), he estimated 
nutritional selenium deficiency to be highly prevalent (>50%) in 21 countries and moderately 
prevalent (10-50%) in a further 16 countries (Combs, 2001).  He also points out that the extent of 
the problem may be greater, as there is little or no information for most of Africa, South America 
and central and south Asia.  Against this background and with new research evidence regularly 
appearing for the role of selenium in the reduction of viral virulence (Beck et al. 1995, 1998, 2001) 
and cancer risk (Li et al. 2004; Yoshizawa et al. 1998; Yu M-W et al. 1999; Helzlsouer et al. 2000; 
Nomura et al. 2000; Brooks et al. 2001; van den Brandt et al. 2003; Wei et al. 2004), it is not 
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surprising that many people are interested in ensuring they have adequate selenium status by 
supplementing their diets with selenium.  
 
Selenium supplements available in order of increasing cost include:- the inorganic forms, sodium 
selenite, sodium hydrogen selenite and sodium selenate; organic forms, high-selenium yeast (Se-
yeast) and the seleno-amino acid, L-selenomethionine (SeMet), the major selenium species in Se-
yeast.  Although all these supplements have been available without any apparent associated 
problems for many years, the European Parliament and Council of the EU issued a directive in 2002 
(Directive 2002/46/EC) on permitted food supplements, specifying a so-called  “positive list”, 
which included inorganic forms of selenium but excluded organic forms such as selenomethionine 
and Se-yeast.  Thus organic forms of selenium will no longer be able to be sold in the EU from 
August 2005, or from January 2010 in the case of countries that asked prior to August 2003 for 
postponement of this directive.  In the latter case, a dossier supporting the safe use of any particular 
form of organic selenium has to be received by the European Commission by July 2005 and then 
approved by the European Food Safety Authority.  This decision was based on the opinion of the 
EC Scientific Committee on Food (SCF) that Se-yeast supplements were poorly characterised with 
regard to nature and quantity of selenium components and because of the fear that selenium from 
SeMet could build up in body tissues to toxic levels.  Given the relatively low cost, good 
bioavailbility and wide popularity of Se-yeast supplements, which appear to be the most-commonly 
purchased form of single-nutrient selenium supplement in Europe, it seems timely to examine the 
validity of the concerns raised by the EU in relation to Se-yeast.  Before discussing these issues, it is 
helpful to have an idea of the different species involved in the biosynthesis of selenium compounds 
by yeast and their metabolism by humans as laid out below.   
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Biosynthesis and metabolism of selenium compounds with special reference 
to Se-yeast 
Cereals and forage crops convert selenium mainly into SeMet and incorporate it into protein in 
competition with methionine.  In the same manner, Saccharomyces cerevisiae (bakers’ or brewers' 
yeast) may assimilate up to 3000 µg/g selenium, the major product being SeMet which is 
incorporated into yeast proteins or physically associated with macromolecules, especially cell-wall 
constituents (Demirci, 1999; Polatajko et al. 2004).  Figure 1 shows the biosynthetic pathways in 
plants and yeast that relate to the formation of SeMet.  SeMet formed biosynthetically is the L-
isomer and where SeMet from yeast is mentioned hereafter, it should be understood to be L-SeMet.  
A number of other organic selenium compounds are also formed as described in detail by Whanger 
(2004). 
 
The metabolic fate of SeMet and other organic selenium compounds from the human diet [e.g. 
selenocysteine (SeCys), Se-methyl-Se-cysteine (CH3SeCys)] is shown in Fig. 2 (adapted from 
Combs, 2001).  SeMet from Se-yeast and food proteins can be incorporated non-specifically into 
proteins such as albumin and haemoglobin in place of methionine.  Alternatively it can be trans-
selenated to SeCys which is then converted to hydrogen selenide (H2Se) by a β-lyase.  The H2Se 
formed may be converted to selenophosphate (HSePO32-) by selenophosphate synthetase.  
Selenophosphate reacts with tRNA-bound serinyl residues to give selenocysteine-bound tRNA from 
which selenocysteine is inserted co-translationally, at loci encoded by specific UGA codons, to give 
selenoproteins (Berry et al. 1991, 1993).  
 
Excess selenium is detoxified by successive methylation of H2Se, yielding methyl selenol 
(CH3SeH), dimethyl selenide [(CH3)2Se] and trimethyl selenonium ion [(CH3)3Se+], the latter two 
of which are excreted in breath and urine respectively.  Se-methyl-Se-cysteine (CH3SeCys), 
apparently present to a small extent in Se-yeast (Bird et al. 1997; Kotrebai et al. 2000; Larsen et al. 
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2001) and in some foods, notably Allium and Brassica vegetables (Kotrebai et al. 2000, Whanger, 
2004), is acted upon by another β-lyase to give CH3SeH directly (Combs, 2001).  There is some 
evidence for direct formation of CH3SeH from SeMet by action of a γ-lyase, also known as 
methioninase (Nakamuro et al. 1997; Spallholz et al. 2004; Wang et al. 2002).  [CH3SeH and its 
precursor Se-methyl-Se-cysteine are believed to be potently anticarcinogenic and antiangiogenic 
(Ip, 1998; Whanger, 2004).]  
 
Oxidised inorganic forms (selenate, selenite), undergo reductive metabolism yielding H2Se, the 
starting point for the manufacture of selenoproteins as described above.  Oxidation of excess H2Se 
can lead to the production of superoxide and other reactive oxygen species (Combs, 2001).  
 
The ratio between incorporation of SeMet into body proteins and the formation of alternative more-
active metabolic products will depend on the amount of dietary methionine [though this is generally 
only an issue in animal studies where diets may be methionine-poor (Sunde 1997)] and presumably 
on the history of SeMet intake.  After a sufficient period of ingestion of SeMet (or Se-yeast), a state 
of equilibrium may be reached wherein turnover from the general protein pool is able to supply 
SeMet metabolites (Schrauzer 2001) at a level associated with health effects (Rayman 2000). 
 
 
Manufacture and quality control of Se-yeast production 
Se-yeast is the product of the aerobic fermentation of Saccharomyces cerevisiae in a selenium-
enriched medium.  Different companies use different strains of Saccharomyces cerivesiae and may 
describe them either as bakers' or brewers' yeast.   The medium is usually beet or cane molasses to 
which are added vitamins, nutritional salts and other growth factors to ensure maximal biomass, and 
measured amounts of selenium salts (e.g. sodium selenite) as the selenium source.  Control of pH, 
temperature, selenium feeding profile and aeration allow optimal growth of the yeast strain and 
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maximum biomass production.  A selenium-enriched yeast cream is produced that is then 
pasteurised thereby killing the yeast, and dried, frequently by spray-drying.  One company (Pharma 
Nord, Denmark) does not use molasses because of the inherent variability of such a material but 
instead prefers to grow the yeast on pure glucose syrup with appropriate pharmacopoeia-grade 
additives in order to produce a pharmaceutical-grade, species-constant Se-yeast. 
 
As a result of the fermentation in the selenium-enriched medium, the selenium becomes organically 
bound to the yeast.  The amount bound should be greater than 90%, typically 94% (percentage of 
complexed organic selenium found in three lots of LAMIN™ Se-yeast by KABS Laboratories, St. 
Hubert, QC, Canada) in the case of one manufacturer (Lallemand, Canada).  In this case, Lallemand 
R&D reported that around 83% of the selenium in the yeast was bound to yeast proteins, including 
cell-wall proteins.  
 
Reputable manufacturers of Se-yeast ensure that their material is of good quality by carrying out the 
following checks or analyses on a routine basis:- assessment of the purity of the yeast strain (by 
biochemical and genetic identification techniques), the percentage of complexed organic selenium 
and the percentage of selenomethionine; measurement of particle size, moisture content and of the 
level of toxic impurities (arsenic, cadmium, lead, mercury) and microbiological contaminants which 
must meet required purity criteria. 
 
Unfortunately not all material sold as Se-yeast is produced according to these stringent criteria.  
Sometimes the percentage of sodium selenite is such that most of the selenium is clearly not bound 
to the yeast: at worst, there may merely be a mixture of sodium selenite and yeast, the selenium not 
being bound to the yeast (Uden et al. 2003).   Thus a customer may not be getting what he/she has 
paid for i.e. an organically-bound selenium source that contains a good proportion of SeMet.  While 
this may not matter in most cases, there is an issue of bioavailability.  SeMet has the capacity to be 
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assimilated non-specifically into normal body proteins in place of methionine thus acting as a 
potential reservoir for selenium (Combs, 2001; Thomson et al. 1993).  Sodium selenite, though a 
good selenium substrate for the formation of selenoproteins, cannot be stored for later use (Alfthan 
et al. 1991). 
 
It should be noted that Se-yeast is not just manufactured for human consumption.  There is a 
burgeoning market in Se-yeast as an FDA-approved selenium supplement for livestock, where Sel-
Plex™ (Alltech) is probably the market leader. 
 
 
Species contained in Se-yeast – speciation 
The wide use of Se-yeast in nutritional and intervention studies such as the Nutritional Prevention 
of Cancer Trial in the US that showed a significant reduction in cancer incidence and mortality with 
a 200 µg Se-yeast supplement (Clark et al. 1996), has spurred analysts on to identify the selenium 
species, other than SeMet, that are present in Se-yeast.  Such “speciation” studies are difficult, 
requiring a combination of state-of-the-art techniques and advanced instrumentation.  
 
The main difficulty is how to preserve the identity of the selenocompounds during their extraction 
from the yeast, prior to analysis using chromatographic and mass spectrometric techniques.  Water 
has been used to extract high- and low-molecular-weight species (Polatajko et al. 2004; McSheehy 
et al. 2002) but the extraction efficiency is low, around 10-15 % of the total selenium in the yeast.  
Proteolytic hydrolysis with non-specific enzymes, mostly Protease XIV, has given 60-80 % 
recovery of the total selenium content in the dry yeast, mostly as SeMet.  However with this 
method, it is not possible to distinguish between species that have undergone degradation and those 
that have not. 
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Separation of selenium compounds can then be achieved by a number of methods such as size-
exclusion, cation or anion exchange high performance liquid chromatography (HPLC) (Lobinski et 
al. 2000; Larsen et al. 2004) or reversed-phase ion-pair HPLC (Lobinski et al. 2000; Uden et al. 
2003).  Intact selenium-containing proteins from Se-yeast have also been successfully separated by 
two-dimensional gel electrophoresis (2-D SDS PAGE) (Chassaigne et al. 2004).  Selenium-specific 
detection is generally by inductively coupled plasma mass spectrometry (ICP-MS).  Alternatively, 
for volatile compounds and selenoaminoacid-volatile-derivatives, gas chromatography with 
detection by atomic emission (AED) has been used (Uden et al. 2003).  The use of tandem mass 
spectrometry on selenium-containing fractions gives the possibility of identification of species for 
which standards do not yet exist.  Matrix-assisted laser desorption ionisation time-of-flight 
(MALDI-TOF) MS with electrospray MS have been used successfully to identify selenium species 
including selenopeptides (Encinar et al. 2003).   
 
Owing to the differences in manufacturing method referred to above, and to the varying extraction 
techniques and analytical methods used in different laboratories, it is hardly surprising that analysis 
of Se-yeast gives a variety of results.  Analyses of commercially-available Se-yeast preparations 
have shown organically-bound selenium to vary from 0-97% of the total selenium content (Uden et 
al. 2003).  Even for the same yeast batch, results can vary somewhat between laboratories.  
Depending on the extraction technique, the yield and therefore the ratio of molecules such as SeMet 
to total selenium can differ slightly.  For example, the same batches of LALMIN™ selenium yeast 
(Lallemand, Canada) analysed by two laboratories gave percentages of SeMet as 58% (Danish 
Veterinary and Food Administration Laboratory) and 65% (Ultra Traces Analyses Aquitaine, 
UT2A, Pau, France) of total selenium, probably reflecting the difference in extraction efficiencies, 
calculated as 78% in the first case and 93% in the second case.  Both laboratories however found 
very little variation in the ratio of SeMet to total selenium in different batches (1.6% and 1.5% 
RSD) indicating the reproducible quality of the Se-yeast.   
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In Se-yeast digests from reputable manufacturers, SeMet is the major single component: 58-65% 
(see above) of total selenium in LALMIN™ (Lallemand, Canada); 60-70% of total selenium in 
SelenoExcell™ (Cypress Systems, Fresno, California); 54-60% of total selenium in SelenoPrecise™ 
(Pharma Nord, Denmark) (Uden at al. 2003; Larsen et al. 2004), 62-74% in Sel-Plex™ (personal 
communication Dr. Ronan Power, Alltech, Kentucky 2004), with the caveat that the quoted figures 
are dependent on the extraction efficiency of the technique used by the analytical laboratory.   
 
Good-quality Se-yeast preparations such as those described above should not contain more than 1% 
of inorganic selenium, the remainder having been converted to organic species or washed from the 
Se-yeast.  Intermediates formed in the biosynthesis or metabolism of SeMet (see Fig. 1) such as Se-
homocysteine, Se-cystathionine, and γ-glutamyl-Se-methyl-Se-cysteine have also been identified in 
addition to analogues of sulphur metabolites such as Se-adenosyl-Se-homocysteine (Bird et al. 
1997; Uden et al. 2003).  The metabolite Se-methyl-Se-cysteine has also been reported in digested 
Se-yeast extracts on the basis of its matching retention time with a standard of that substance (Bird 
et al. 1997; Kotrebai et al. 2000; Larsen et al. 2001).  Aqueous yeast extracts have also shown the 
presence of selenodiglutathione (GS-Se-SG), a metabolite of selenite, and the mixed 
selenotrisulphide of glutathione and cysteinylglycine (GS-Se-SCG) (Lindemann & Hintelmann, 
2002).  Molecules identified in digested extracts as a percentage of eluted selenium from enzymatic 
hydrolysates of various commercially available Se-yeasts are given in Table 3.  The data on the two 
commercial yeasts (believed to be Selenomax, personal communication, Prof. Peter Uden 2004) 
illustrate the difference in species and percentages that can occur in yeasts of different total 
selenium content.  Note that SeMet-selenoxide or its hydrate are products of oxidation of SeMet and 
are probably analytical artefacts (Larsen et al. 2003; Uden at al. 2003) not present in the original 
samples. 
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While the table shows the wide variety of compounds that have been identified in Se-yeast, direct 
comparison between samples may be misleading owing to the application of different methods of 
analysis in different laboratories.  
 
As explained above, a number of Se-yeasts appear to contain small amounts of Se-methyl-Se-
cysteine (0.5%) or its precursor, γ-glutamyl-Se-methyl-Se-cysteine (0.5%).  One study has reported 
Se-methyl-Se-cysteine to account for as much as 25% of the total yeast selenium in a sample of 
Nutrition 21 (Selenomax™) Se-yeast  (El-Bayoumy et al. 2002).  However the authors of this paper 
point out that the imputed presence of Se-methyl-Se-cysteine was based on co-chromatography with 
a synthetic standard and that the method they used was, at best, only semi-quantitative (personal 
communication, Bogdan Prokopczyk, 2003).  Furthermore the analysis for Se-methyl-Se-cysteine 
was performed on samples that were two-years old.  The presence of Se-methyl-Se-cysteine and γ-
glutamyl-Se-methyl-Se-cysteine is of interest as these species are believed to be metabolised in 
animals and humans to methyl selenol (CH3SeH), a potent anticarcinogen (Ip, 1998).  Among the 
unidentified Se-yeast products, it is possible that there may be other organoselenium species that 
may also be more-potent anticarcinogens than SeMet.   
 
Archived samples of Se-yeast (Nutrition 21) tablets used in the Nutritional Prevention of Cancer 
Trial (Clark et al. 1996) have been analysed by two laboratories and have been found to contain a 
number of unknown selenium compounds (Larsen et al. 2004; Uden at al. 2003).   Uden and co-
workers (2003) have identified not only SeMet-selenoxide (hydrate), the oxidation product of 
SeMet referred to above, but also a hitherto unreported Se-S bonded product, S-(selenomethyl)-
cysteine.  It is of course not known if these compounds were present in the yeast tablets at the time 
of the trial nor if they have any health effects, though it seems possible that SeMet-selenoxide is 
equivalent in action to SeMet (Uden et al. 2003).  In any case it is readily reduced back to SeMet by 
glutathione (Arteel et al. 1999). 
 13
 
In conclusion, it seems fair to say that Se-yeast products from reputable manufacturers contain 
almost all their selenium organically bound and around 55 to 75% of it (allowing for extraction 
efficiency) in a form that hydrolyses to SeMet.  Smaller amounts of other selenium compounds, 
including at least one precursor of the potently anticarcinogic methyl selenol, and an oxidation 
product of SeMet, SeMet-selenoxide (hydrate) have also been identified in the enzymic extracts.  
Apparent substantial qualitative and quantitative differences between Se-yeasts may be at least 
partly a result of different techniques and analytical procedures applied in different laboratories.   
 
 
Bioavailability of Se-yeast 
Bioavailability is conventionally defined as the fraction of ingested nutrient that is utilised for 
normal physiological functions (Fox et al. 2004).  As there is no direct method of measuring 
bioavailability, absorption and retention of the nutrient are taken as indirect measures of 
bioavailability (Fox et al. 2004).  Absorption of selenium is not homeostatically regulated and is not 
believed to be affected by nutritional status.  
 
A few dietary factors are known to affect the bioavailability of selenium.  Protein is said to enhance 
its bioavailability (Combs, 1988), presumably because methionine from protein competes with 
SeMet for incorporation into body proteins thus making SeMet more bioavailable for short-term 
use.  In humans, vitamin C appears to improve the bioavailability of selenium from a mixed diet 
(Fairweather-Tait, 1997).  Combs (1988) describes vitamin A (high levels), vitamin E and 
antioxidants as enhancers of the bioavailability of dietary selenium in animals.  Substances that 
appear to reduce its bioavailability include guar gum, which reduces selenium absorption in humans 
(Fairweather-Tait, 1997), heavy metals and high dietary sulphur which are described as inhibitors of 
bioavailability in animals (Combs, 1988).  As many selenium compounds are absorbed by the same 
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mechanism as their sulphur analogues, the absorption of a number of selenium species from Se-
yeast may be reduced by high dietary sulphur intake.   
 
Absorption of dietary selenium (organic selenium) is generally believed to be good - around 80% 
from food (Reilly, 1996).  Absorption and retention of Se-yeast have been measured in 12 male 
subjects fed 77Se-labelled SelenoPrecise™ yeast (Pharma Nord, Denmark), as 90% and 75% 
respectively (Sloth et al. 2003).  Using the same methodology, a different form of Se-yeast gave a 
lower absorption and retention - 53.5% and 59.3% respectively (Fox et al. 2004). The reasons for 
the different results between the two studies may relate to the strain of the yeast and more-
importantly to the difference between the processes used to prepare the Se-yeast.  The Fox et al. 
study used non-pasteurised brewers’ yeast, flask-grown in the laboratory to enrich it with 77Se and 
freeze-dried, rather than the commercially produced, pasteurised (dead), spray-dried, bakers' yeast 
(SelenoPrecise™) used in the first bioavailability study.  Temperature, time of fermentation and 
nature of selenium source (selenious acid) were also different from those normally used in 
manufactured products (personal communication Dr. Henri Durand, Lallemand, 2004).  Forced 
aeration is not possible in flask-grown yeast resulting in low biomass production and low selenium 
incorporation into amino acids (personal communication Dr. Ronan Power, Alltech, 2004).  Thus 
the selenium concentration of the Fox et al. Se-yeast was reported as 145 µg/g dry yeast, almost 
ten-fold lower than the 1400 µg selenium/g of SelenoPrecise™.  Furthermore, the heat treatment 
(pasteurisation) to which commercial Se-yeast products are subjected kills the yeast and causes the 
disintegration of the yeast cells thereby improving their digestibility (personal communication Dr. 
Henri Durand, Lallemand, 2004).  It is hardly surprising, therefore, that the measured absorption 
and retention of the Se-yeast used in the study of Fox and colleagues was lower than that of a 
commercial product and it is unlikely to be representative of Se-yeasts on the market. 
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A number of supplementation studies have indicated that the selenium from Se-yeast is more 
bioavailable than from inorganic selenium (with one exception, Fox et al. 2004, see below) and that 
increased selenium status is retained for a longer period after supplementation has ceased.  This is 
undoubtedly due to the non-specific incorporation of SeMet from digested yeast proteins into tissue 
proteins such as skeletal muscle, erythrocytes and plasma albumin from which it can subsequently 
be released by catabolism to maintain increased selenium status for a time.  Some examples of 
supplementation studies are given below. 
 
The bioavailability of selenium from Se-yeast has been shown to resemble that of wheat selenium 
rather than inorganic selenium (selenate) in its effect on plasma selenium (Levander et al. 1983).  
Three groups of ten men of low selenium status were given 200 µg selenium/day as selenium-rich 
wheat, selenium-rich yeast, or sodium selenate for 11 weeks.  Twenty unsupplemented subjects 
served as controls.  Ten weeks after the supplements were discontinued, plasma selenium and 
platelet glutathione peroxidase were higher in the wheat and yeast groups than in the selenate group 
(see Fig. 3).  Fig. 3 shows the remarkable similarity in the behaviour of wheat and yeast selenium 
both in terms of their capacity to raise plasma selenium and in the rate of decline of selenium status 
after withdrawal of supplementation.   
 
In a study carried out by Alfthan and colleagues (1991), men were supplemented with 200 µg 
selenium/d in the form of selenate, selenite and Se-yeast.  Se-yeast and selenite increased plasma 
selenium after 11 weeks from 110 µg/L to peak values of 170 and 125 µg/L, respectively. Thus the 
effect of Se-yeast supplementation was more pronounced than that of inorganic selenium 
supplementation but the levels did plateau after 11 weeks and did not continue to increase 
indefinitely.  Post-supplementation, the decrease in plasma and erythrocyte selenium levels was far 
less pronounced in the Se-yeast group than in the groups supplemented with inorganic selenium, 
taking longer to return to baseline levels. 
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Similarly, a three-month Danish study of selenium supplementation in humans, suggested that 
organic selenium (selenomethionine and high Se-yeast) is more bioavailable than selenate and 
selenite (Clausen & Nielsen, 1988).  Both the inorganic and the organic selenium supplements gave 
rise to steady-state levels of glutathione peroxidase after one month but whole-blood levels of 
selenium continued to rise for longer in those receiving organic selenium.  This did not happen, 
however, in the study of Schrauzer and White (1978), who found that a steady state of selenium in 
whole blood was reached about two months after supplementing human subjects with 150 µg/d of 
Se-yeast. 
 
Thirty-three New Zealand women aged 18-23 years received daily for 32 weeks, 200 µg selenium 
as Se-yeast, or brewer's yeast mixed with selenate, or no added selenium (placebo) in a double-blind 
trial (Thomson et al. 1993).  Se-yeast was more effective in raising blood selenium concentrations 
than selenate, but both were equally effective in raising glutathione peroxidase activities in whole 
blood, erythrocytes and plasma, indicating a similar bioavailability of the two forms in terms of 
increasing selenoenzyme activity. 
 
Kumpulainen demonstrated that 100 µg/d of Se-yeast is more effective than the same dose of 
selenite in increasing maternal serum selenium in breast-feeding mothers (Kumpulainen et al. 
1985).  The selenium levels plateaued within six months of initiation of the yeast supplementation.  
In contrast to that finding, a Polish study showed no significant difference between the selenium 
intake of breast-fed infants whose mothers were supplemented with 200 µg/d of Se-yeast or sodium 
selenite for three months (Trafikowska et al. 1998).  Supplemental Se-yeast was, however, shown to 
be beneficial in preventing the longitudinal decline in milk selenium content that occurred with 
advancing lactation (McGuire et al. 1993).  When US women were supplemented with 200 mcg/d 
Se-yeast from 4 to 8 weeks post-partum, infant plasma selenium concentration at the end of the 
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supplemented period was 83 µg/L in the infants of supplemented mothers compared to 63 µg/L in 
the control infants (McGuire et al. 1993).   
 
Pre-term infants experience significant selenium depletion (Daniels, 1996).  The impact of Se-yeast 
on the serum selenium concentration of pre-term infants living in a low selenium area (Hungary) 
was determined (Bogye et al. 1998).  Although the bioavailability of selenium in the form of yeast 
selenium was higher than that of other selenium compounds used for pre-term infants, no 
complications or side-effects owing to enteral yeast selenium supplementation were observed.   
 
Not all studies have found yeast selenium to be more bioavailable than inorganic selenium.  The 
study of Fox and colleagues (2004) supplemented thirty-five male volunteers with isotopically-
labelled selenium as selenate (82Se, reference dose) and trout fish (raw or cooked, 74Se) or yeast 
(77Se) in order to compare the apparent absorption and retention of selenium from these different 
sources.  Absorption of yeast selenium was lower than that of fish selenium (60%) and considerably 
lower than that of selenate (58%).  Retention of selenium yeast was significantly lower than that of 
fish selenium (69%) and somewhat lower than that of selenate (95%).  Thus this recent study 
showed that yeast selenium was less-well-absorbed and less-well-retained in the body than 
inorganic selenium.  However, as explained above, this yeast was not typical of manufactured Se-
yeasts which may explain the different results obtained.  
 
There is some evidence that Se-yeast can raise selenium status to normal levels in situations where 
inorganic selenium cannot do so.  One human and two animal examples are given.  Administration 
of selenium as Se-yeast and SeMet significantly increased plasma selenium levels up to the normal 
range in rheumatoid arthritis patients when selenite supplementation was unable to do so (Heinle et 
al. 1997, Peretz et al. 1992). 
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Selenite and selenate have a limited capacity to increase the concentration of selenium in milk from 
dairy cows.  This is a problem in Sweden where suckling calves are at risk of selenium deficiency.  
The following two studies carried out in Sweden illustrate that Se-yeast is much more effective than 
inorganic selenium in increasing the concentration of selenium in milk.  (i) When dairy cows were 
supplemented with selenium as sodium selenite, selenate or Se-yeast, selenium concentration rose 
to a plateau in plasma at four weeks from 50 µg/l (control) to 75 µg/l (selenite), 80 µg/l (selenate) 
and 90 µg/l (selenium yeast).  Milk concentration rose from 14 µg/l in the control group to 16.4, 
16.4 and 31.2 µg/l in the selenite, selenate and Se-yeast groups respectively showing that Se-yeast 
was much more effective in raising the selenium concentration in milk (Ortman & Pehrson, 1999).  
(ii) Supplementation of the suckler cows' diet with Se-yeast rather than sodium selenite improved 
the selenium status of their calves (otherwise considered to be marginal).  In practice, such 
supplementation would probably eliminate the existing risk of nutritional muscular degeneration in 
suckling calves (Pehrson et al. 1999).   
 
The contrast between the bioavailability of Se-yeast and SeMet is illustrated by a study by McGuire 
and colleagues (1993).  The impact of providing SeMet or Se-yeast on the selenium status of 
lactating and non-lactating women was studied.  Plasma selenium declined in un-supplemented 
lactating women but not in non-lactating women.  SeMet increased plasma selenium in both 
lactating and non-lactating women whereas Se-yeast increased plasma selenium only in non-
lactating women.   Plasma glutathione peroxidase activity decreased with duration of lactation in 
unsupplemented women and SeMet or Se-yeast supplementation prevented the decline.  Milk 
selenium declined markedly for 20 weeks after parturition in unsupplemented women.  SeMet 
significantly increased milk selenium concentrations whereas selenium yeast prevented a decline.  
 
In summary, the studies quoted show that Se-yeast is both able to increase selenoenzyme activity 
and furthermore, unlike selenite or selenate, can be stored as SeMet in tissues, giving it a slower 
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whole-body turnover rate and allowing it to support greater tissue selenium concentrations than 
inorganic selenium.   However its apparently lower bioavialbility compared to SeMet (McGuire et 
al. 1993) presumably reflects the fact that the yeast has to be degraded and that not all the selenium 
in Se-yeast is in the form of SeMet.  Reported whole-body half-lives of SeMet and selenite in 
humans were 252 and 102 days respectively, implying that SeMet is retained 2.5 times longer in the 
body than selenite (Schrauzer, 2000).  Accordingly, humans or animals supplemented with Se-yeast 
can maintain higher activities of selenoenzymes during selenium depletion for longer periods than 
those supplemented with inorganic selenium owing to the recycling of SeMet following catabolism 
from protein stores.  These factors are an advantage in situations of low to marginal selenium status, 
such as exist notably in some European countries or in groups such as pre-term infants.  Yeast 
selenium is also more effective than inorganic selenium in its ability to transfer selenium to breast-
fed infants or suckling animals, thereby preventing the risk of deficiency.   
 
 
Use of Se-yeast in intervention studies 
A number of human intervention studies, as summarised below, have used Se-yeast as the 
intervention agent to good effect.   
Cancer prevention studies  
No controlled human cancer prevention studies have been carried out with any form of selenium 
other than Se-yeast.  It is thus impossible to know if other forms i.e. inorganic selenium, or even 
SeMet, would have the same anti-cancer effects that have been shown for Se-yeast. The following 
intervention studies have used Se-yeast, the first in combination with other agents. 
i. NCI sponsored trials in China for the prevention of oesophageal cancer observed significant 
reductions in total mortality and stomach-cancer mortality in the intervention arm containing 
Se-yeast, β-carotene, and vitamin E (Blot et al. 1993).  Some nine years later, results from 
the same study showed significant inverse associations between baseline serum selenium 
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and death from esophageal squamous cell carcinoma (RR: 0.83; 95% CI: 0.71-0.98) and 
gastric cardia cancer (0.75; 0.59-0.95) (Wei et al. 2004).  The authors have suggested that 
population-wide selenium supplementation in the region of China with low serum selenium 
and high incidences of these cancers should be seriously considered.  
ii. The Nutritional Prevention of Cancer (or NPC) Trial, was designed to test the hypothesis 
that selenium supplementation could reduce the risk of cancer (Clark et al. 1996).  In 1312 
subjects with a history of non-melanoma skin cancer who were randomised in a double-
blind manner to placebo or 200 µg Se/day (as Se-enriched yeast), there was no effect on the 
primary end-point of non-melanoma skin cancer.  However, those receiving Se showed 
secondary end-point effects of 50% lower total cancer mortality (p = 0.002) and 37% lower 
total cancer incidence (p = 0.001) with 63% fewer cancers of the prostate, 58% fewer 
cancers of the colon and 46% fewer cancers of the lung.  In a reanalysis of the data to 
include a further 25 months of blinded treatment and follow-up, Se-yeast supplementation 
significantly reduced total cancer incidence by 25% and prostate cancer incidence by 52% 
but although lung and colorectal cancers were reduced (by 26% and 54% respectively), 
these effects did not reach significance (Duffield-Lillico et al. 2002).  The protective effect 
was stronger in males and those with lower baseline plasma selenium concentrations 
(<121.6 µg/L). 
iii. In the Qidong county, around 40 miles north of Shanghai, the incidence of hepatocellular 
carcinoma (HCC) is particularly high.  In this region around 15% of adults carry the 
Hepatitis B surface antigen and these people are 200 times more likely to develop HCC.  In 
a study where 226 Hepatitis B antigen carriers were randomised to either 200 µg of Se-yeast 
or placebo, no case of HCC occurred in the supplemented group after four years, while 
seven subjects in the placebo group had developed HCC (Yu SY et al. 1997).  However, as 
full details of the methodology of this study are not available, it is difficult to assess whether 
its protocol was sufficiently well-controlled or robust to be confident in its conclusions. 
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iv. A double-blind randomised, placebo-controlled trial of Se-yeast was carried out in 36 
healthy adult males, 19-43 years of age, for a period of nine months.  Beneficial effects were 
seen in the selenium-supplemented group that were not seen in the control group, namely a 
32% increase in blood glutathione (GSH) levels (p<0.05) and a significant decrease in 
prostate specific antigen (p<0.001), suggesting a protective effect against prostate cancer 
with Se-yeast supplementation (El-Bayoumy et al. 2002). 
v. Se-yeast was shown to be effective in reducing the tumour yield in an animal model of 
breast cancer induced by methylnitrosourea (Ip et al. 2000) 
 
Rheumatoid arthritis  
In a double-blind randomised controlled trial in a small group of rheumatoid arthritis patients, 
supplementation with 200 µg selenium as Se-yeast for three months, gave a significant reduction in 
pain (p < 0.01) and joint involvement (p< 0.05) (Peretz et al. 1992).     
 
Patients with rheumatoid arthritis were supplemented with 600 µg/d "selenmomethionine-
containing yeast" (presumably Se-yeast) enriched with vitamin E for eight months in a double-blind 
manner.  Significant alleviation of articular pain and morning stiffness was observed and no adverse 
effects were seen (Aaseth et al. 1998).  
 
Immune response in the elderly 
Selenium appears to be able to reverse the age-related decline in immune response in the elderly.  In 
a group of 22 institutionalised elderly subjects supplemented with 100 µg Se-yeast/d or placebo for 
six months, response to mitogen challenge was restored to the level of that in healthy young people 
in those receiving the selenium (Peretz et al. 1991). 
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HIV-progression 
186 HIV-positive men and women with plasma selenium concentration in the "adequate" range 
(>85 µg/L), were supplemented with 200 µg/day Se-yeast (Selenomax® Nutrition 21) from 1998-
2000 in a randomised, double-blind, placebo-controlled clinical trial (Burbano et al. 2002). In-
patient hospitalisations, hospitalisation costs, and rates of hospitalisation were determined two years 
before and during the trial.  A marked decrease in total admission rates (RR = 0.38; p = 0.002) and 
percent of hospitalisations due to infection/100 patients, for those receiving selenium was observed 
(p = 0.01).  The cost of hospitalisation decreased by 58% in the selenium group compared to 30% in 
the placebo group (p = 0.001).  In the final analysis, selenium therapy continued to be a significant 
independent factor associated with lower risk of hospitalisation (RR of hospitalisation, placebo vs. 
selenium 2.44, 95% CI 1.31-4.53, p = 0.01).   Furthermore, the number of subjects with CD4 cell 
counts >50 declined by 46% in the placebo group but only by 25% in the selenium-treated group (p 
= 0.01).  It was concluded that selenium supplementation was a beneficial adjuvant treatment in 
HIV-1-infected patients (Burbano et al. 2002). 
 
Further studies using Se-yeast 
Se-yeast (Cypress Systems) is currently being used in further prostate cancer studies at the Arizona 
Cancer Center at doses of 200-800 µg/d:- the Negative Biopsy Trial (Stratton et al. 2003a), the 
Preprostatectomy Trial (Marshall, 2001) and the Watchful Waiting Trial (Stratton et al 2003b).  In 
the UK, the SELINA (SELenium IN Asthma) trial has been underway since 2002 using a dose of 
100 µg/d (SelenoPrecise™, Pharma Nord) or placebo (Co-Principal Investigators Shaheen and 
Rayman).   
 
Further studies using Se-yeast are planned though funding has not yet been secured: the SPRINT 
Trial (Selenium in PRegnancy INTervention) investigating the effect of 60 µg/d vs. placebo on the 
 23
risk of pre-eclampsia in the UK (Principal Investigator Rayman, Rayman et al. 2003), and the 
international PRECISE (PREvention of Cancer by Intervention with Selenium) trial which will use 
doses of 0, 100, 200 and 300 µg/d in 42,000 volunteers recruited through the internet. 
 
 
Toxicity 
It is generally accepted that inorganic forms of selenium are more acutely toxic than organic forms 
such as Se-yeast.  There is data on toxicity of Se-yeast from two animal studies while a number of 
human intervention studies show that chronic administration of Se-yeast provides no evidence of 
toxicity. 
 
Acute toxicity and animal studies 
Acute toxicity studies with Se-yeast have been carried out on rats (Vinson & Bose, 1987).  The 
LD50 for selenium yeast was 37.3 mg/kg compared with 12.7 mg/kg for sodium selenite 
demonstrating that Se-yeast is considerably less acutely toxic than sodium selenite (Figure 4).  A 
further study comparing the toxicity of a selenite and a Se-yeast diet in rats also showed that Se-
yeast was much less toxic than selenite (Spallholz & Raftery, 1987).  Severe hepatotoxicity, 
cardiotoxicity and splenomegaly were observed in rats fed selenite at levels of 16 µg/g dietary 
selenium over an eight-week period whereas animals fed high-Se-yeast at the same level showed no 
such symptoms.  Although the livers of animals fed Se-yeast showed up to 50% greater deposition 
of selenium, there was no corresponding toxicity, as evidenced by histological examination 
(Spallholz & Raftery, 1987). 
 
Chronic toxicity - human studies 
It has been suggested that organic forms of selenium may be more toxic during long-term 
consumption as they can be incorporated into tissue proteins rather than excreted rapidly.  Signs of 
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selenosis are hair loss, brittle, thickened and stratified nails, garlic breath and skin lesions (Whanger 
et al. 1996). 
 
Long term supplementation studies with Se-yeast have been carried out by four research groups:- 
Arizona Cancer Center, University of Arizona, first led by Dr. Larry Clark and later (following his 
death), by Dr. Jim Marshall with Dr. Mary Reid; Cancer Institute, Chinese Academy of Medical 
Sciences, Beijing by Dr. Shu Yu Yu and colleagues; The UK PRECISE study group at the 
University of Surrey in collaboration with the Institute of Cancer Research led by Dr. Margaret 
Rayman; The Danish PRECISE study group at Odense University Hospital led by Dr. Søren Cold 
in collaboration with Prof. Kim Overvad of the University of Aarhus.  These studies are described 
below followed by a description of a medium-term human study with high dose Se-yeast and a 
short-term study in lactating women.  
 
University of Arizona, Arizona Cancer Center studies:  In the Nutritional Prevention of Cancer 
(NPC) Trial, a total of 1312 subjects whose baseline intake was around 90 µg Se/d, were randomly 
allocated to receive supplements of 200 µg of selenium as Se-yeast (Nutrition 21, brewers' yeast) or 
placebo yeast for a mean of 4.5 years (Clark et al. 1996).  After a mean of 6.5 years of follow-up, 
significant reductions in total cancer mortality (down by 50%) and total cancer incidence (down by 
37%) were seen in the selenium group.  A total of 35 subjects complained of adverse effects, most 
of which involved gastrointestinal upset, resulting in their withdrawal from treatment.  Of these, 21 
were in the selenium-group and 14 in the placebo group.  Within each group, those reporting 
adverse effects did not have significantly different plasma selenium concentrations from those not 
reporting such effects.  
 
Longer-term follow-up data on selenium status from this trial than previously published (Clark et 
al. 1996) is shown in Figure 5 (personal communication, Dr. Mary Reid and Dr. Jim Marshall, 
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2003).  It can be seen that administration of 200 µg/d Se-yeast gives a rapid increase in plasma 
selenium up to about three months, after which the increase levels off reaching a clear plateau at 
around 190 µg/L by one year.  This plasma selenium level is well below that associated with 
toxicity (1054-1854 µg/L in whole blood, generally 23% higher than in plasma, Yang et al. 1989)  
 
Currently there are three trials underway using doses up to 800 µg/d of high-Se yeast from Cypress 
Systems (California) (Marshall, 2001):- (i) the Negative Biopsy Trial, where 700 men with 
persistently-elevated prostate-specific antigen are randomly allocated to placebo or 200 µg or 400 
µg selenium/d  with a follow-up period of 57 months (Stratton et al. 2003a); (ii) the 
Preprostatectomy Trial, where 110 men with localised prostate cancer are supplemented with 200 
µg or 400 µg selenium/d between biopsy and prostatectomy; (iii) the Watchful Waiting Trial, where 
men with localised prostate disease and a life expectancy of < 10 years receive 200 µg or 800 µg 
selenium/d as Se-enriched yeast (Stratton et al. 2003b).  There have been no safety concerns in this 
trial even after supplementation with 800 µg Se-yeast/d for three years or more (Stratton et al. 
2003b) and according to Marshall (2001), no evidence of any toxicity in any of these trials.  This is 
consistent with the NOAEL of 819±129 µg/d from dietary selenium determined by Yang and Zhou 
(1994). 
 
In an arm of the Watchful Waiting Trial that was discontinued in 2001, eight subjects were 
randomised to a dose of 1600 µg Se-yeast/d and 16 subjects to a dose of 3200 µg/d (Reid et al. 
2004).  Subjects were on these doses for average periods of almost 12 months.  Mean plasma 
selenium levels achieved were 492 (SD 188) and 640 (SD 491) µg/L respectively.  While the 3200 
µg/d group reported more selenium-related side effects such as garlic breath, brittle nails and hair, 
stomach upset and dizziness than the 1600 µg/d group, blood chemistry and haematology results 
were all within normal limits.  No severe or serious selenium-related toxicity was observed in either 
 26
group but these doses were discontinued because of the lack of safety information in the literature 
relating to these doses (Reid et al. 2004). 
 
Studies from the Cancer Institute, Chinese Academy of Medical Sciences, Beijing: Two hundred 
and twenty six Hepatitis Surface-Antigen Positive subjects were provided 200 µg Se yeast or 
placebo yeast daily for four years.  No side-effects were reported (Yu SY et al. 1997).   
 
Studies from the PRECISE Study Group at the University of Surrey: A pilot study for the UK 
PRECISE (PREvention of Cancer by Intervention with SElenium) Trial, funded by the Cancer 
Research Campaign, was initiated in October 1999.  In this double-blind placebo-controlled pilot 
study, 500 male and female volunteers, aged 60-74, were randomised from June 2000.  The study 
had four treatment groups: placebo, 100, 200, and 300 µg/day of selenium as Se-yeast 
(SelenoPrecise™, Pharma Nord, Vejle, Denmark).  Randomisation was stratified to give groups that 
were equivalent in terms of numbers, age and gender. 
 
Up to the end of January 2003, 16 subjects (3.2%) had withdrawn because of abdominal or stomach 
problems and 16 (3.2%) had withdrawn because of other adverse effects.  Of the 32 subjects who 
reported adverse effects, 7 (22%) were on placebo, 8 (25%) were taking 100 µg of selenium, 7 
(22%) were taking 200 µg of selenium and 10 (31%) were taking 300 µg of selenium.  None of the 
subjects in the 300 µg group developed hair or nail problems, known signs of selenium toxicity.  
Chi-squared tests on withdrawals due to adverse events show that there was no significant 
difference in:- the number of abdominal/stomach problems in the four treatment groups (X2 = 0.5, 
df = 3, p = 0.92); the number of other adverse events in the four groups (X2 = 0.57, df = 3, p = 
0.57); the number of total adverse effects by treatment group (X2 = 0.75, df = 3, p = 0.86). 
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Nor was the mean selenium status of those suffering adverse effects significantly different from the 
mean of their treatment group (p>0.05).  Although mean plasma selenium rose significantly in all 
treatment groups except placebo demonstrating good bioavailability of the Se-yeast, at 227 µg/g 
(233 µg/L) (Larsen et al. 2004), the level attained in the 300 µg/d treatment group was well within 
safe limits.   
 
Thus from this study there is no evidence of toxic effects associated with Se intakes of 340 µg/d 
(300 µg/d from Se-yeast and approximately 40 µg/d from diet) over a maximum period of 2 years 
and 8 months, and plasma levels of 233 µg/L. 
 
Studies from the PRECISE study group at the Odense University Hospital: A pilot study for the 
Danish PRECISE (PREvention of Cancer by Intervention with SElenium) Trial, was initiated in 
December 1998 (Larsen et al. 2004).  In this double-blind placebo-controlled pilot study, as in the 
UK cohort, 500 male and female volunteers, aged 60-74, were randomised to one of four treatment 
groups: placebo, 100, 200, and 300 µg/day of selenium as Se-yeast (SelenoPrecise™ Pharma Nord, 
Vejle, Denmark).     
 
Up to the end of August 2003, 23 subjects (4.6%) had withdrawn because of adverse effects.  Of the 
23 subjects who reported adverse effects, 8 (35%) were on placebo, 3 (13%) were taking 100 µg of 
selenium, 8 (35%) were taking 200 µg of selenium and 4 (17%) were taking 300 µg of selenium 
(personal communication, Dr. Søren Cold, 2004).  Neither the distribution nor the severity of side 
effects correlated with the intake of selenium.  The Chi squared test applied to withdrawals due to 
adverse effects shows that there was no significant difference in the number of total adverse effects 
by treatment group (X2 = 3.61, df = 3, p = 0.31).   
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Mean (SD) whole-blood selenium concentration in 13 subjects from the 300 µg/d treatment group 
two-years after randomisation was 441 (132) µg/L (Larsen et al. 2004), similar to the level reported 
by Yang and colleagues (1983) to be safe, i.e. without evidence of selenosis.  Thus from this study 
there is no evidence that selenium intakes up to 343 µg/d (300 µg/d from the Se-yeast supplement 
and approximately 43 µg/d from diet) over a maximum period of 4 years and 8 months, and whole-
blood levels of 441 µg/L, are associated with toxic effects.   
 
As the UK and Danish PRECISE Pilot Studies used the same protocol with respect to 
randomisation and treatment, withdrawals owing to adverse effects up to 24 months from 
randomisation in both pilots have been combined into a single table (Table 4).  Chi squared tests on 
these data show clearly that there is no difference in adverse effects between the treatment groups 
(X2 = 1.83, df = 3, p = 0.61) showing that Se-yeast supplementation is without toxic effects even 
after chronic dosage at 300 µg/d. 
 
Medium term human study with high dose Se-yeast: Patients with rheumatoid arthritis were 
supplemented with 600 µg/d "selenmomethionine-containing yeast" (presumably Se-yeast) enriched 
with vitamin E for eight months in a double-blind manner.  Though a significant alleviation of 
articular pain and morning stiffness was observed, no adverse effects were reported (Aaseth et al. 
1998).  Plasma selenium plateaued at 500 µg/L at four months.  
 
Short-term study with Se-yeast in lactating women: A Polish study supplemented lactating 
mothers for three months with 200 µg/d selenium as Se-yeast or sodium selenite (Trafikowska et al. 
1998).  Supplementation with Se-yeast resulted in an increase in infant intake from 6.1 µg/d to a 
level of 11.3-12.8 µg/d that reached a plateau after one month.  There was no significant difference 
between the selenium intake of these infants and of those whose mothers were supplemented with 
200 µg/d as sodium selenite.  The infant selenium intake achieved was four- to five-fold lower than 
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the Upper Limit of 45-60 µg/d recommended for infants of 0-12 months (Food and Nutrition Board 
2000).  At the end of three months, the infants supplemented with Se-yeast had plasma 
concentrations of 87 µg/L and whole blood concentrations of 102 µg/L.  Comparison of the latter 
concentration with mean whole-blood values of 440-968 mcg/L that are associated with safe intakes 
of selenium (Yang et al. 1983, Yang & Zhou, 1994) leads to the conclusion that there is 
considerable leeway between the supplementation level of 200 µg g/d and the maximum level of 
Se-yeast that can safely be consumed without harm to the infant.  
 
On this point, Dorea (2002) has commented that selenium appears in breast milk as a component of 
specific selenoproteins and seleno-amino-acids in milk proteins that are well-tolerated by breast-fed 
infants even in high amounts.  This is consistent with the lack of evidence of increased sensitivity to 
selenium toxicity at younger ages (Food and Nutrition Board, 2000) and with Kim and Mahan's 
observation that nursing pigs are capable of buffering against excess of milk selenium (organic) by 
storing more selenium in body tissues (Kim & Mahan, 2001). 
  
Summary of toxicity data 
The EU Scientific Committee on Food (SCF) expressed the concern in 2002 that organic selenium 
e.g. SeMet or Se-yeast could build up in body tissues to toxic levels.  The evidence presented here 
is reassuring in that respect, showing that selenium reaches a plateau in plasma after 11 weeks to 6 
months, depending on the subjects and the study (Alfthan et al. 1991; Aaseth et al. 1998; 
Kumpulainen et al. 1985), and in whole blood after about two months, following selenium yeast 
supplementation (Schrauzer & White, 1978).  In line with results of the latter study, selenium levels 
plateaued in erythrocytes after six weeks of selenomethionine supplementation (Luo et al. 1987). 
There are no published studies on tissue levels of selenium following long-term administration of 
Se-yeast though there are some in progress that will determine tissue levels of selenium in muscle 
biopsies from human volunteers that have been taking organic selenium for varying lengths of time 
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up to 20 or 30 years (personal communication, Deitrich Behne 2004).  However, there is at present 
no evidence that Se-yeast supplementation causes a continuing rise in tissue selenium.  According 
to Schrauzer (2001), at constant intakes of SeMet (as from Se-yeast), a steady state is established 
which is maintained indefinitely and over a large range of intakes owing to the release of SeMet 
from body proteins during protein turnover which occurs continuously.  In any case, the large 
number of intervention studies quoted that have used Se-yeast in doses of 200, 300, 400 and even 
800 µg/d for lengthy periods (up to 12 years in the case of the 200 µg dose) without any indication 
of toxic effects, implies that there cannot be a continuing rise in tissue selenium and supports the 
assertion that this form of Se-supplementation is no more hazardous than supplementation with 
inorganic selenium.  This conclusion is supported by the observation that thousands of people living 
in South Dakota are, and have been, exposed to high intakes of organic selenium for over a century 
without adverse effects: no evidence of selenium toxicity was found in subjects whose intakes were 
as high as 724 µg/d  (Longnecker et al. 1991). 
 
In fact, the obligatory conversion of organic selenium (such as Se-yeast) into an inorganic form 
(H2Se) may be an important regulator of Se bioavailability in that it may confer protection against 
excessive incorporation of selenium into selenoproteins and prevent toxicity mediated through 
reactive oxygen species (see Figure 2), from excessive intakes (Brown et al. 2000). 
 
Bearing in mind the fact that selenium recommendations for infants are currently not achieved in 
30% of breast-milk samples measured world-wide (Dorea. 2002) and that infants in Europe are 
more at risk of not meeting recommendations than infants from most other countries (Dorea, 2002), 
Se-yeast, as an inexpensive supplement, should help prevent inadequacy in this vulnerable group. 
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Se-yeast in the fortification of foods 
Should some of studies currently underway indicate a significant benefit of a higher selenium 
intake, Se-yeast may be an excellent fortificant for foods.  It provides a biological barrier between a 
cheap selenium source – inorganic selenium – and the individual consumer, reducing the risk of 
overdose.  Evaluation of Se-yeast products with regard to shelf life indicates good long-term 
stability, 36 months or more (personal communications Nadine Renard, Lallemand, 2004 & Sven 
Moesgaard, Pharma Nord 2004).   
 
Se-yeast is a pasteurised (dead), generally spray-dried, finely divided powder that has none of the 
unpleasant smell associated with SeMet and could readily be added to flour to increase the selenium 
content of bread.  Se-yeast (LALMIN™, Lallemand) is stable to baking showing an excellent 
correlation (R2 = 0.999) between the expected amount of total selenium per slice and the quantity 
expected (personal communication, Nadine Renard, Lallemand, 2004).  By the same token, Se-
yeast would be suitable for other food products, particularly those in powder form or drinks. 
 
The use of Se-yeast to supplement the diet of cows has been shown to be considerably more 
effective than inorganic selenium in raising the concentration in milk and cheese (Malbe et al. 1995; 
Ortman & Pehrson, 1999). 
 
Benefits and drawbacks of Se-yeast as a selenium source  
There are a number of drawbacks associated with Se-yeast.  A few individuals are allergic to yeast 
for whom this form of supplement would clearly be unsuitable, but this is not a common problem.  
The major drawback to this source of selenium is likely to be perceived as its variability with 
respect to its selenium content and speciation.  Furthermore, we are still some way away from full 
identification of all the selenium species that can occur in Se-yeast.  However, if it is purchased 
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from reputable manufacturers operating good quality control and quality assurance schemes, the Se-
yeast will be of reproducible nature and Se-Met content.  
 
The fear that selenium from SeMet in Se-yeast proteins could build up in body tissues to toxic 
levels appears to be unsubstantiated.  The ability to be stored in the organism and reversibly 
released by normal metabolic processes to counteract periods of insufficient intake is an advantage 
in areas of low selenium intake that exist in various parts of the world.  The problem in countries of 
the EU is not selenium toxicity, but marginal or deficient selenium status that has worsened in some 
countries in recent years as a result of a fall in imports of North American wheat following their 
accession to the EU (Rayman, 1997).  In Eastern Europe in particular, many populations have mean 
levels of serum or plasma selenium insufficient to optimise plasma glutathione peroxidase activity 
(Rayman, 2000).  Se-yeast, as the most inexpensive organic selenium supplement, could be 
particularly appropriate in these situations.  Concerns about selenium toxicity are more properly 
reserved for regions of the world where selenium intakes are naturally high, such as some parts of 
China, Venezuela and the Great Plains of the US where supplementation with selenium-yeast, 
SeMet or indeed any form of selenium would be inadvisable. 
 
While Se-yeast appears to be a less-effective anticarcinogen in animal studies than Se-methyl-Se-
cysteine (CH3SeCys), the form produced in selenium enriched garlic and broccoli, and slightly less 
effective than selenite (Ip 1998; Ip et al 2000), it is none-the-less the only form of selenium to date 
to have shown efficacy in human anti-cancer intervention studies (Clark et al. 1996; Yu et al. 1997; 
Blot et al. 1993).  It is also a better precursor for selenoprotein synthesis than Se-methyl-Se-
cysteine which is largely converted directly to methyl selenol (Ip, 1998).   
 
It should be noted that selenium-enriched foods, of which Se-yeast may be considered an example, 
contain mixtures of different selenium compounds that are metabolised uniquely and can therefore 
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affect multiple pathways (e.g. to inhibit carcinogenesis).  Furthermore, they have been shown to 
have equal or higher chemopreventive activity in animal models than purified compounds (Davis & 
Finley, 2003): though the major selenium compound in high-selenium wheat is SeMet, in rats 
injected with a chemical carcinogen, a high-selenium wheat diet significantly reduced aberrant 
colon crypts and aberrant crypt foci while pure SeMet was unable to do so (Finley & Davis, 2001).  
 
Reilly (1996) has pointed out that foods normally contain organic forms of selenium, with the 
inorganic forms only entering the diet as supplements or contaminants while Schrauzer (2001) has 
stated that selenium should be supplemented in the form or forms in which it occurs in major staple 
foods.  Se-yeast is the nearest product to food-form selenium, being apparently handled similarly to 
high-selenium wheat (Levander, 1983), that is readily available for fortification or supplementation.  
 
 
Conclusion 
The evidence presented here has shown Se-yeast to be a safe, bio-available form of selenium that 
mimics food-form selenium, suitable for use in food supplements, that can act both as a precursor 
for selenoprotein synthesis and as a human anti-cancer agent.  When manufactured by reputable 
manufacturers, the product is of reproducible quality and defined SeMet content.  Even over long 
periods of supplementation at levels of 300, 400 or even 800 µg/d, Se-yeast has shown no evidence 
of toxicity. 
     
The ability of selenium from Se-yeast to be stored in the organism and reversibly released by 
normal metabolic processes to counteract periods of insufficient intake is likely to be particularly 
valuable in areas of low-selenium intake such as exist in Eastern Europe.   
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There is therefore no justification for disallowing the sale of Se-yeast in Europe, particularly if the 
guidelines relating to Upper Safe Limits (e.g. the rather-conservative EC Tolerable Upper Intake 
Level of 300 µg/d) are adhered to (EC Scientific Committee on Food, 2000).  
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Table 1. Current recommended selenium intakes for adults (µg/d) (EC Scientific Committee on 
Food 2003; Thomson 2004) 
 
RDA/RNI/PRI/NR Country/Region 
M F 
Australia, 1990 85 70 
Belgium, 2000 70 70 
DACH (Germany, Austria, Switzerland), 2000 30-70 30-70 
EC Scientific Committee on Food, 2003 55 55 
France, 2001 60 50 
Italy, 1996 
Japan, 1999 
55 
55-60 
55 
45 
New Zealand/Australia (proposed levels) 65 55 
Nordic Countries, 1996 50 40 
USA and Canada, 2000 55 55 
UK, COMA,1991 75 60 
WHO/FAO/IAEA, 1996 40 30 
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Table 2. Selenium intake data for a number of countries 
 
Country Selenium intake 
(µg/person/d) 
Reference 
Australia 57-87  Fardy et al. 1989 
Austria 48  Simma & Pfannhauser 1998 (cited by Combs, 2001) 
Belgium 28-61  Robberecht et al. 1994  
Czech Republic 10-25 (estimate) Kvícala et al. 1996 
Canada 98-224 Gissel-Nielsen 1998 (cited by Combs, 2001) 
China 7-4990 Combs, 2001 
Croatia 27  Klapec et al. 1998 (cited by Combs, 2001) 
Denmark 38-47 Danish Government Food Agency, 1995 
France 29-43 Lamand et al. 1994 
Germany  35  Alfthan G & Neve J, 1996 
Japan 104-199  Miyazaki et al. 2001 
Netherlands 39-54  
67  
van Dokkum 1995 
Kumpulainen, 1993 
New Zealand 55-80  Vannoort et al. 2000 
Poland 30-40 (calculated) Wasowicz et al. 2003 
Serbia 30  Djujic et al. 1995 
Slovakia 38 Kadrabová et al 1998  
Sweden 31  
38 
Swedish National Food Administration, 1989 
Kumpulainen, 1993  
Switzerland 70 Kumpulainen, 1993 
UK 29-39 MAFF, 1997 
USA 106  Food and Nutrition Board 2000 
Venezuela 200-350 Combs & Combs, 1986 (cited by Combs, 2001) 
 
 54
Table 3. Selenium species identified in aqueous extracts of commercial samples of selenium yeast 
following enzymatic hydrolysis, expressed as a percentage of extracted selenium (N.B. Percentages 
are dependent on the extraction efficiency of the technique used and the total selenium content of 
the yeast - see text.) 
Yeasts  
 
Se-Species 
SelenoExcell† 
1250 µg Se/g 
dry yeast  
LALMIN† 
2119 µg Se/g 
dry yeast 
SelenoPrecise† 
1327 µg Se/g  
dry yeast 
Sel-Plex† 
1800 µg 
Se/g  
dry yeast 
Selenomax† 
1200 µg 
Se/g dry 
yeast 
Selenomax† 
2100 µg 
Se/g dry 
yeast  
SeMet  84% 69% (75%)* 81% 83% 61% 60% 
selenite  0.1% <1% (nd/nr)* nd/nr 0.3% 15% 1% 
γ-glutamyl-Se-
methyl-Se-cysteine  
0.5% nd/nr (nd/nr)* nd/nr nd/nr 0.5% 0.5% 
Se-methyl-Se-
cysteine 
nd/nr nd/nr (nd/nr)* nd/nr nd/nr 0.5% 0.5% 
Se-adenosyl-Se-
homocysteine  
0.5% nd/nr (nd/nr)* nd/nr nd/nr 5% 2% 
Se-cystathionine nd/nr nd/nr (nd/nr)* nd/nr nd/nr 1% 0.5% 
Se-lanthionine nd/nr nd/nr (nd/nr)* nd/nr nd/nr nd/nr 0.5% 
Se-cystine nd/nr nd/nr (nd/nr)* nd/nr nd/nr 0.5% 0.5% 
Se-cysteine nd/nr 3% (nd/nr)* nd/nr 5% nd/nr nd/nr 
SeMet-selenoxide 
/hydrate  
nd/nr nd/nr (nd/nr)* 0.4% nd/nr nd/nr nd/nr 
Methaneseleninic 
acid 
nd/nr nd/nr (nd/nr)* nd/nr nd/nr nd/nr nd/nr 
Sum of identified 
species 
85.1% 72% (75%)* 81.4% 88.3% 84% 67% 
Laboratory P. Uden R. Lobinski  
(E. Larsen) 
E. Larsen R. Lobinski P. Uden P. Uden 
Reference Uden et al. 
2003 
 H. Durand 
(pers. comm.) 
Larsen et al. 
2004 
R. Power, 
pers. comm. 
2004 
Kotrebai et 
al. 2000 
Kotrebai et 
al. 2000 
nd/nr = not determined/not reported 
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*results from two different laboratories, the second in parentheses 
†SelenoExcell, formerly Selenomax, Cypress Systems, Fresno, California; LALMIN, Lallemand, Montreal, Canada; 
SelenoPrecise, Pharma Nord, Vejle, Denmark; Sel-Plex, Alltech, Lexington, Kentucky 
Nutrition 21, manufacturer of Selenomax, was asked for similar information but did not respond.
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Table 4. Summary data from UK and Danish PRECISE Pilot Studies (1000 randomised subjects) 
on withdrawals up to 24 months from randomisation.  
 
Treatment group UK Pilot study 
withdrawals 
Danish Pilot study 
withdrawals 
Total number 
of withdrawals 
placebo 7 6 13 
100 µg/d 8 0  8 
200 µg/d 7 7 14 
300 µg/d 10 3 13 
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Fig. 1. Proposed pathways for the metabolism of selenium in plants (adapted from Whanger 2004).  
Compounds in bold have been identified in aqueous extracts of Se-yeast. 
 
 
Fig. 2. The metabolic fate of SeMet and other organic selenium compounds [e.g. selenocysteine 
(SeCys), Se-methyl-Se-cysteine (CH3SeCys)] from the human diet (adapted from Combs 2001). 
 
 
Fig. 3. Effect of selenium supplementation on plasma selenium level of middle-aged Finnish men of 
low selenium status.  Each point represents the mean ± SEM of 8 to 20 subjects per group (from 
Levander et al. 1983). 
 
 
Fig. 4. LD50 for sodium selenite and Se-yeast in rats.  
 
 
Fig. 5. Mean plasma selenium in selenium-treated and control groups in the NPC trial (figure 
adapted from that of Clark et al. 1996) (N.B. Units on the x axis are not evenly spaced). 
